Archimedes, Inc. designs and develops healthcare management solutions. The company offers ARCHeS Innovator, an application that focuses on the treatment of cardio-metabolic diseases; Archimedes IndiGO, a decision support tool; and Forecast Datasets, a system that focuses on policy and guideline analysis and performance measurement. Additionally, it provides disease modeling, clinical trial simulation, and healthcare consulting services. The company’s clientele include American Board of Internal Medicine, Daiichi-Sankyo, GlaxoSmithKline, GE Healthcare, Genetic Technologies, and Oxerigen Therapeutics. Archimedes, Inc. was founded in 2006 and is based in San Francisco, California. As of January...
201 Mission Street
San Francisco, CA 94105
Founded in 2006
Archimedes, Inc. Announces Results of a Simulated Clinical Trial
Dec 5 13
Archimedes Inc. announced results of a simulated clinical trial which found that the seven single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was most cost effective when used to guide MRI screenings for patients found to have an intermediate lifetime risk of developing the disease. The study, "Cost-effectiveness of a genetic test for breast cancer risk," appeared in the December 5(th) online issue of the peer-reviewed journal Cancer Prevention Research. In 2007, the American Cancer Society recommended MRI as an adjunct to mammography for the screening of breast cancer in women who have a lifetime risk of breast cancer of approximately 20% to 25% or greater as determined by models based on family history such as the Gail test. In the virtual study, researchers used Archimedes' detailed simulation model of breast cancer risk factors, disease progression, and healthcare processes to estimate the costs and benefits of using genetic testing to refine estimates of risk for purposes of referring women to MRI screening. The simulation included growth, detection, and spread of tumors, as well as screening and treatment. The model compared two tests to categorize patients by lifetime risk, the Gail risk test and the 7SNP test. The Gail model, which is widely used by the National Cancer Institute, estimates risk using information on age, race, family history, and age of menarche and first live birth. The 7SNP genetic test uses the genotype of the patient to refine the estimate of the Gail test. In the simulated study, average-risk patients received an annual mammogram and high-risk patients received an annual MRI. The simulated population consisted of 100,000 non-Hispanic white women starting at the age of 40 with no prior history of cancer and a lifetime Gail risk of breast cancer of at least 10%. Cancer incidence was based on Surveillance, Epidemiology, and End Results (SEER) data and validated to the Cancer Prevention Study II (CPS-II) Nutrition Cohort dataset. Risk factors were drawn from the National Health and Nutrition Examination Survey (NHANES-4) and Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial data. Mammogram characteristics were derived from Breast Cancer Surveillance Consortium data. For patients with a lifetime risk of at least 10%, the model showed that the 7SNP test results in a 2.7% reduction in cancer deaths relative to the Gail test alone. For patients with a risk of 16% to 28%, the 7SNP test saved 0.005 quality-adjusted life years (QALY) per person at a cost of $163,264 per QALY. The cost effectiveness of using the 7SNP test for patients with intermediate Gail risk is similar to that of other recommended strategies, including annual MRI for patients with a lifetime risk greater than 20% or BRCA1/2 mutations, for which the model estimated a cost of $141,415 per QALY, relative to mammogram. Additional background about the study and the abstract is available here. This study was a collaborative project between Archimedes and Genetic Technologies Ltd.
Archimedes, Inc.'s Archimedes IndiGO Chosen by Risk-Assessment Engine for the New $100,000 Mobile App
Feb 27 13
Archimedes IndiGO, the physician and patient decision-support tool created by Archimedes, Inc. was chosen last summer as the risk-assessment engine for the new $100,000 mobile app challenge sponsored by the Office of the National Coordinator. As part of the U.S. Department of Health and Human Services' Million Hearts(TM) 'Risk Check Challenge,' the ONC invited developers to create a mobile app that would help consumers take a heart-health risk assessment, direct them to health-screening locations in their community, and use the results to work with their doctor to develop a plan for improving their heart health.